Science Policy
ddobbs | May 7, 2008From Well, Tara Parker-Hope's health blog at the NY Times:
More than half of the task force members who will oversee the next edition of the American Psychiatric Association’s most important diagnostic handbook have ties to the drug industry, reports a consumer watchdog group.
The Web site for Integrity in Science, a project of the Center for Science in the Public Interest, highlights the link between the drug industry and the all-important psychiatric manual, called the Diagnostic and Statistical Manual of Mental Disorders. The handbook is the most-used guide for diagnosing mental disorders…
revere | May 5, 2008Mrs. R. and I visited Australia a number of years back. She was the one attending a scientific congress while I was the accompanying spouse. Quite nice, really. I enjoyed not having to work on a foreign visit. And Australia was terrific. We loved it. I was surprised at how good the food was (a baseless prejudice I had about Commonwealth Cuisine) and the people hospitable and friendly. Much like America, really. Unfortunately the Australian government is becoming too much like the US government when it comes to interfering in science:
A paper recently published in the Australian and New…
scientificactivist | April 29, 2008Last Thursday (April 24), the Senate unanimously passed the Genetic Information Nondiscrimination Act of 2008 (GINA, H.R. 493) in a landmark vote. The goal of this bill is "to prohibit discrimination on the basis of genetic information with respect to health insurance and employment," and it therefore would help fill this gaping hole that exists in our current protection of employees' and patients' rights.
The bill was passed by the House roughly one year ago by a vote of 420-3, and although it was scheduled for debate in the Senate, it wasn't voted upon until last week. Now, the Senate has…
revere | April 28, 2008On a couple of occasions (here, here) we've taken note of the scientific controversy regarding the plasticizer, bisphenol-A (BPA). I shouldn't really put it this way, because as the leading BPA researcher, Fred vom Saal of the Univeristy of Missouri said in the Washington Post over the weekend, there is no meaningful controversy any longer. Now that NIH's National Toxicology Program has finally presented its draft report on BPA expressing concern over possible carcinogenic and developmental effects, vom Saal's statement seems pertinent:
"The scientific community basically said, 'This argument…
evolgen | April 21, 2008Someone was asked something along these lines by a member of some legislative body:
How will your research help protect this country?
That someone replied with something like this:
It won't, but it will keep this country worth protecting.
The exact wording in those quotes probably differ from what was actually said.
This isn't a rhetorical question, nor is it an exercise in trivia. I don't know who said it, what the exact context of the quote was, or whether this was actually said by anyone, anytime, anywhere. So, if you know of the exact quote, who said it, and where it was said, please…
evolgen | April 13, 2008Harold Varmus is one of the most high profile advocates of open access to biomedical research. As one of the cofounders of the Public Library of Science (PLoS), he has played an important role in making published results freely available to all. And he's a Nobel Laureate, which ain't too shaby either.
Varmus was interviewed by Ira Flatow for NPR's Science Friday program about the NIH's new policy requiring that research publications presenting results funded by the NIH be deposited in PubMed Central (the NIH's free online archive of biomedical journal articles) within a year of publication.…
ddobbs | April 8, 2008It seems that the rise in ER use comes not from the poor uninsured but from a much more affluent income sector.
From the Wall St. Journal Health Blog:
Rich, Not Poor, Are Crowding Emergency Rooms:
This is the conventional wisdom: Priced out of health insurance, ever more Americans are crowding into emergency rooms because they can’t afford a trip to the doctor.
Yes, ERs are getting busier. But it’s not because of poor people or the uninsured, according to this analysis in the Annals of Emergency Medicine.
The study is based on national surveys conducted between 1996 and 2004. During that…
revere | April 6, 2008About a month ago (March 1, 2008) we brought you the story of how a highly reputable and knowledgeable scientist, Dr. Deborah Rice of the Maine Department of Maine Department of Health and Human Services, was bonced off of an EPA scientific advisory committee because the chemical industry trade group, the American Chemistry Council (ACC), objected that she had a bias. How did they know? Dr. Rice, as part of her duties as toxicologist for the State of Maine, testified before its legislature that on the basis of a review of the scientific evidence she believed the deca congener of the…
ddobbs | March 21, 2008Some great stuff I've come across, lack time to blog on, but would hate for you to miss:
In On being certain, neurologist and novelist Robert Burton, who writes a column at Slate Salon, looks at the science of what makes us feel certain about things -- even when we're dead wrong about them. His book on the subject, which I read in advance copy a while back, is fascinating fun reading. The most startling (and disorienting) finding he describes is that, from a neurocognitive point of view, our feeling of certainty about things we're wrong about is pretty much indistinguishable from our…
ddobbs | March 6, 2008Why aren't your wages going up? Maybe because you're the one paying for the health insurance your boss is supposedly paying for.
That's the gist of a new commentary in JAMA, which I'd missed till the Health Blog at the Wall Street Journal brought it to my attention: "Who Really Pays for Health Care?," the recent commentary by bioethicist Ezekiel Emanuel and economist Victor Fuchs, argues that employer-provided health care is not as valuable a benefit as it is cracked up to be because employers basically pull it from pay raises employees would get otherwise. The result, the article says, is…
ddobbs | March 6, 2008A quick heads-up: Nature weighs in on the flap over the Kirsch SSRI study that found antidepressants no more effective than placebo. I've given a lot of attention to the placebo issue. Nature stresses another point: That the Kirsch study underscores the need for clinical trial data to be public. At present it is not, as the drug companies have persuaded the FDA that releasing all trial data might reveal trade secrets. Nature argues -- as have many -- that what's being hidden is not proprietary trade secrets but information vital to public health:
No more scavenger hunts
The recent media…
scientificactivist | March 3, 2008Via the ABC News blog Political Punch comes news that senator and Republican presidential candidate John McCain has taken a strong stance on the discredited link between vaccination and autism... a stance contrary to scientific consensus. Here's what Jake Tapper wrote:
At a town hall meeting Friday in Texas, Sen. John McCain, R-Ariz., declared that "there's strong evidence" that thimerosal, a mercury-based preservative that was once in many childhood vaccines, is responsible for the increased diagnoses of autism in the U.S. -- a position in stark contrast with the view of the medical…
ddobbs | February 29, 2008The ripples from the PLOS Medicine antidepressants-don't-work study by Kirsch et alia, which I covered below, just keep spreading. Those who want to follow it can do well by visiting or bookmarking this search I did (an ingenious Google News search for "Kirsch SSRI"). It seems to be tracking the press coverage pretty well. Note that the heavier and higher-profile coverage comes mainly from UK. As far as I can tell, none of the top 3 or 4 US papers have yet covered it.
This blog search should help as well.
Some of the more notable responses since yesterday:
Science weighs in. The Times…
ddobbs | February 28, 2008The Kirsch study I wrote about a couple days ago, which found that antidepressants seem to have no more effect than placebo, has generated a wide variety of reactions in the blogosphere and press. Several things of note here:
1) In a pattern I've noticed repeatedly of late about other types of stories about things in the U.S., this story got much more attention in the British press than it did here in the U.S. (The authors were from the UK, but the paper was published in a U.S.-based journal, and antidepressant use is a huge issue in the U.S.)
2) The responses -- some by bloggers, writers,…
cevans | February 25, 2008As a blogger, I usually willfully delineate a giant chasm of non-communication between myself and political issues, preferring to dabble in the absolute: time, space, theoretical technological infrastructures, and, recently, aliens. I wrote one very reticent entry in 2005 about chimeric research, prefacing it with the pronouncement that "this blog will rarely concern iself with Pressing Science Ethics Issues," a statement that has proven in the intervening years to be true.
However, I can't deny that my love of the sciences has blossomed under the steely wing of one of the most anti-science…
revere | February 22, 2008Recently we posted on the insanity of requiring informed consent for posting a hygiene checklist in the ICU. This week the New England Journal of Medicine weighed in.
Here's some background from the NEJM Commentary:
About 80,000 catheter-related bloodstream infections occur in U.S. intensive care units (ICUs) each year, causing as many as 28,000 deaths and costing the health care system as much as $2.3 billion. If there were procedures that could prevent these infections, wouldn't we encourage hospitals to introduce them? And wouldn't we encourage the development, testing, and dissemination…
revere | February 9, 2008Late yesterday afternoon, a Friday and classic time to release news you don't want anyone to read, I got the following email [excerpted] from David Schwartz, on leave as Director of the National Institute of Health Sciences (NIEHS), the main public health-oriented NIH institute and the subject of several previous posts (here, here, here, here, here):
Dear friends and colleagues,
I have decided to resign as director of the NIEHS and NTP, effective immediately. My reasons for this decision are simple. I believe that our institute would be more successful with new leadership, and that I would…
scientificactivist | February 4, 2008
Since the movement for an official presidential debate focused on science was launched in December 2007, Science Debate 2008 has gained momentum continuously. For evidence of this, just check out its news page, or take a look at the long lists of influential organizations and individuals, bloggers, and signatories in general supporting this initiative.
And, as of today, Science Debate 2008 can add a few more to the list:
February 4 -- The National Academy of Sciences, National Academy of Engineering, and Institute of Medicine are joining the American Association for the Advancement of…
revere | January 23, 2008This week sees the tenth anniversary of an important event in the American environmental movement, although few people know it (even some who were there had forgotten the date). In late January, 1998, a group of 32 environmental scientists, activists and scholars sat down together at the Wingspread Conference Center in Racine, Wisconsin to hash out a consensus statement on The Precautionary Principle. After a grueling three days, the statement was put into final form on January 25 (just in time to see my beloved Green Bay Packers lose the Superbowl. Is history repeating itself? Aargh!).
In…
ddobbs | January 17, 2008
I've written before, both here and in print, about how FDA policy and drug company practices have allowed drug makers to publish (and the FDA to base approval on) only the most flattering drug-trial results while keeping less-flattering studies in the drawer. Today a New England Journal of Medicine report shows how things change when you include the results from the drawer: The effectiveness of many SSRIs dives to near placebo-level. This despite that the companies design and conduct most of these trials in a way calculated to produce positive results.
When I wrote on this for Scientific…